Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 136

1.

Levels of soluble Fas/APO-1/CD95 in systemic lupus erythematosus and juvenile rheumatoid arthritis.

Knipping E, Krammer PH, Onel KB, Lehman TJ, Mysler E, Elkon KB.

Arthritis Rheum. 1995 Dec;38(12):1735-7.

PMID:
8849344
2.

Levels of soluble Fas/APO-1 in patients with Behçet's disease.

Hamzaoui K, Hamzaoui A, Zakraoui L, Chabbou A.

Mediators Inflamm. 1998;7(2):111-4.

3.

Soluble Fas (APO-1, CD95) and soluble Fas ligand in rheumatic diseases.

Nozawa K, Kayagaki N, Tokano Y, Yagita H, Okumura K, Hasimoto H.

Arthritis Rheum. 1997 Jun;40(6):1126-9.

PMID:
9182923
4.

Serum levels of soluble Fas/APO-1 (CD95) and its molecular structure in patients with systemic lupus erythematosus (SLE) and other autoimmune diseases.

Jodo S, Kobayashi S, Kayagaki N, Ogura N, Feng Y, Amasaki Y, Fujisaku A, Azuma M, Yagita H, Okumura K, Koike T.

Clin Exp Immunol. 1997 Jan;107(1):89-95.

5.

Lack of correlation between serum soluble Fas/APO-1 levels and autoimmune disease.

Goel N, Ulrich DT, St Clair EW, Fleming JA, Lynch DH, Seldin MF.

Arthritis Rheum. 1995 Dec;38(12):1738-43.

PMID:
8849345
6.

Do elevated levels of serum-soluble fas contribute to the persistence of activated lymphocytes in systemic lupus erythematosus?

Bijl M, van Lopik T, Limburg PC, Spronk PE, Jaegers SM, Aarden LA, Smeenk RJ, Kallenberg GG.

J Autoimmun. 1998 Oct;11(5):457-63.

PMID:
9802929
7.

Relationship of oncogenes (sFas, Bcl-2) and cytokines (IL-10, alfa-TNF) with the activity of systemic lupus erythematosus.

Miret C, Font J, Molina R, Garcia-Carrasco M, Filella X, Ramos M, Cervera R, Ballesta A, Ingelmo M.

Anticancer Res. 2001 Jul-Aug;21(4B):3053-9.

PMID:
11712810
8.

Elevated levels of serum soluble Fas are associated with organ and tissue damage in systemic lupus erythematosus among Chinese.

Hao JH, Ye DQ, Zhang GQ, Liu HH, Dai H, Huang F, Pan FM, Su H, Dong MX, Chen H, Wang Q, Zhang XJ.

Arch Dermatol Res. 2006 Jan;297(7):329-32. Epub 2005 Nov 17.

PMID:
16328345
9.

Serum soluble Fas/APO-1 is increased in patients with primary Sjögren's syndrome.

Fujihara T, Takeuchi T, Tsubota K, Kayagaki N, Yagita H, Okumura K, Abe T.

Clin Rheumatol. 1998;17(6):496-9.

PMID:
9890678
10.

Correlation between serum levels of soluble Fas (CD95/Apo-1) with disease activity in systemic lupus erythematosus patients in Khorasan, Iran.

Sahebari M, Hatef MR, Rezaieyazdi Z, Abbasi M, Abbasi B, Mahmoudi M.

Arch Iran Med. 2010 Mar;13(2):135-42.

11.

Correlation between serum concentrations of soluble Fas (CD95/Apo-1) and IL-18 in patients with systemic lupus erythematosus.

Sahebari M, Rezaieyazdi Z, Nakhjavani MJ, Hatef M, Mahmoudi M, Akhlaghi S.

Rheumatol Int. 2012 Mar;32(3):601-6. doi: 10.1007/s00296-010-1633-9. Epub 2010 Dec 1.

PMID:
21120501
12.

Serum DNase I, soluble Fas/FasL levels and cell surface Fas expression in patients with SLE: a possible explanation for the lack of efficacy of hrDNase I treatment.

Tinazzi E, Puccetti A, Gerli R, Rigo A, Migliorini P, Simeoni S, Beri R, Dolcino M, Martinelli N, Corrocher R, Lunardi C.

Int Immunol. 2009 Mar;21(3):237-43. doi: 10.1093/intimm/dxn142. Epub 2009 Jan 30.

PMID:
19181929
13.

Soluble Fas molecule in the serum of patients with systemic lupus erythematosus.

Tokano Y, Miyake S, Kayagaki N, Nozawa K, Morimoto S, Azuma M, Yagita H, Takasaki Y, Okumura K, Hashimoto H.

J Clin Immunol. 1996 Sep;16(5):261-5.

PMID:
8886994
14.

Patients with systemic lupus erythematosus with high plasma levels of sFas risk relapse.

van Lopik T, Bijl M, Hart M, Boeije L, Gesner T, Creasy AA, Kallenberg CG, Aarden LA, Smeenk RJ.

J Rheumatol. 1999 Jan;26(1):60-7.

PMID:
9918241
15.

Serum sFas/sFasL ratio in systemic lupus erythematosus (SLE) is a function of age.

Turi MC, D'Urbano M, Celletti E, Alessandri C, Valesini G, Paganelli R.

Arch Gerontol Geriatr. 2009;49 Suppl 1:221-6. doi: 10.1016/j.archger.2009.09.032.

PMID:
19836636
16.

Serum elevations of soluble Fas (CD95/apo-I) concur in deregulating T cell apoptosis during active lupus disease.

Silvestris F, Williams RC, Calvani N, Grinello D, Tucci M, Cafforio P, Dammacco F.

Clin Exp Med. 2002 May;2(1):13-27.

PMID:
12049185
17.

Soluble TRAIL concentrations are raised in patients with systemic lupus erythematosus.

Lub-de Hooge MN, de Vries EG, de Jong S, Bijl M.

Ann Rheum Dis. 2005 Jun;64(6):854-8. Epub 2004 Nov 25.

18.
19.
20.

Transient rise in serum soluble Fas (APO-1/CD95) in patients undergoing cardiac surgery.

Kawahito K, Misawa Y, Fuse K.

Artif Organs. 2000 Aug;24(8):628-31.

PMID:
10971250

Supplemental Content

Support Center